Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1228 ARTÍCULOS , VIENDO DEL 811 AL 825

Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease

Pierrot N, Lhommel R, Quenon L, Hanseeuw B, Dricot L, Sindic C, Maloteaux JM, Octavea JN, Ivanoiu A.

J Alzheimers Dis. 2016;49(2):271-6. doi: 10.3233/JAD-150405.

Dysregulation and diagnostic potential of microRNA in Alzheimer's disease

Pan Y, Liu R, Terpstra E, Wang Y, Qiao F, Wang J, Tong Y, Pan B.

J Alzheimers Dis. 2016;49(1):1-12. doi: 10.3233/JAD-150451.

Circulating microRNAs as Biomarkers of Alzheimer's Disease: A Systematic Review

Wu HZ, Ong KL, Seeher K, Armstrong NJ, Thalamuthu A, Brodaty H, Sachdev P, Mather K.

J Alzheimers Dis. 2016;49(3):755-66. doi: 10.3233/JAD-150619.

Blood-based biomarkers of Alzheimer's disease: diagnostic algorithms and new technologies

Carmona P, Molina M, Toledano A.

Curr Alzheimer Res. 2016;13(4):450-64. doi: 10.2174/1567205013666151116130301.

Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?

Merino JJ, Muñetón-Gómez V, Alvárez MI, Toledano-Díaz A.

Curr Alzheimer Res. 2016;13(4):403-12. doi: 10.2174/1567205013666151116125714.

Testosterone, Estradiol, and Sex Hormone-Binding Globulin in Alzheimer's Disease: A Meta-Analysis

Xu J, Xia LL, Song N, Chen SD, Wang G.

Curr Alzheimer Res. 2016;13(3):215-22. doi: 10.2174/1567205013666151218145752.

Alzheimer's disease: the amyloid hypothesis on trial

Harrison JR, Owen MJ.

Br J Psychiatry. 2016 Jan;208(1):1-3. doi: 10.1192/bjp.bp.115.167569.

Oxidative challenge in Alzheimer's disease: state of knowledge and future needs

Cervellati C, Wood PL, Romani A, Valacchi G, Squerzanti M, Sanz JM, Ortolani B, Zuliani G.

J Investig Med. 2016 Jan;64(1):21-32. doi: 10.1136/jim-2015-000017.

Biochemical and Radiological Markers of Alzheimer's Disease Progression

Dziedzic T, Pera J, Klimkowicz-Mrowiec A, Mroczko B, Slowik A.

J Alzheimers Dis. 2016;50(3):623-44. doi: 10.3233/IFS-150578.

Suspected non-Alzheimer disease pathophysiology--concept and controversy

Jack CR Jr, Knopman DS, Chételat G, Dickson D, Fagan AM, Frisoni GB, Jagust W, Mormino EC, Petersen RC, Sperling RA, van der Flier WM, Villemagne VL, Visser PJ, Vos SJ.

Nat Rev Neurol. 2016 Feb;12(2):117-24. doi: 10.1038/nrneurol.2015.251. Epub 2016 Jan 18.

Rethinking on the concept of biomarkers in preclinical Alzheimer's disease

Berti V, Polito C, Lombardi G, Ferrari C, Sorbi S, Pupi A.

Neurol Sci. 2016 May;37(5):663-72. doi: 10.1007/s10072-016-2477-1. Epub 2016 Jan 20.

Associations Between Genetic Variants in 19p13 and 19q13 Regions and Susceptibility to Alzheimer Disease: A Meta-Analysis

Bao J, Wang XJ, Mao ZF.

Med Sci Monit. 2016 Jan 22;22:234-43. doi: 10.12659/msm.895622.

Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer's Disease

Counts SE, He B, Prout JG, Michalski B, Farotti L, Fahnestock M, Mufson EJ.

Curr Alzheimer Res. 2016;13(7):800-8. doi: 10.2174/1567205013666160129095649.

Metabolomic-Driven Elucidation of Serum Disturbances Associated with Alzheimer's Disease and Mild Cognitive Impairment

González-Domínguez R, Rupérez FJ, García-Barrera T, Barbas C, Gómez-Ariza JL.

Curr Alzheimer Res. 2016;13(6):641-53. doi: 10.2174/1567205013666160129095138.

Amyloid imaging: Past, present and future perspectives

Villemagne VL.

Ageing Res Rev. 2016 Sep;30:95-106. doi: 10.1016/j.arr.2016.01.005. Epub 2016 Jan 28.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias